Tavexia Lifecare Limited (formerly Sattva Sukun Lifecare) approved a ₹67.19 crore strategic acquisition of a 60% stake in Meyonex Pharmaceuticals at its board meeting on October 7, 2026.
The move formalises a proposal first considered by the board on September 7, 2026, when directors were authorised to conduct due diligence, valuation and negotiations for the unlisted target. Meyonex Pharmaceuticals is an unlisted public company.
The acquisition marks Tavexia's entry into pharmaceutical manufacturing through the unlisted target.
The deal also comes against a shifting ownership picture: promoter-group entity Roshan Dealmark Private Limited sold 11,50,000 shares across September 24–28, 2026, trimming aggregate promoter holding from 3.947% to 3.647%.
The transaction remains subject to the completion of definitive agreements and regulatory disclosures to the BSE under SEBI's listing regulations.
Why it matters for founders
Listing entities are increasingly buying their way into pharma and specialty chemicals rather than building greenfield — for founders running profitable niche manufacturers (APIs, intermediates, nutraceuticals), this is an acquisition market, not just a funding market. Due-diligence readiness (clean books, unencumbered assets) is what converts a board 'proposal' into a signed deal.